InsiderTrades.com logo
Global crypto currency reset (41 major banks signed up)
From Stansberry Research   |   Ad
Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...
 Here's everything you need to know.

CNSP Insider Trading

Insider Ownership Percentage: 3.88%
Insider Buying (Last 12 Months): $39,240.00
Insider Selling (Last 12 Months): $0.00

CNS Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at CNS Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

CNS Pharmaceuticals Share Price & Price History

Current Price: $0.21
Price Change: ▲ Price Increase of +0.01 (5.00%)
As of 04/23/2024 01:00 AM ET

This chart shows the closing price history over time for CNSP up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
From Traders Agency   |   Ad
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Click here now for the full details of this stock that’s set to rocket in the AI revolution…

CNS Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/22/2023Christopher DownsCFOBuy27,000$1.27$34,290.0036,772View SEC Filing Icon  
8/16/2023John M ClimacoCEOBuy2,750$1.80$4,950.0049,010View SEC Filing Icon  
4/19/2023Jerzy GumulkaDirectorBuy2,500$1.70$4,250.009,673View SEC Filing Icon  
4/17/2023Christopher DownsCFOBuy3,100$3.20$9,920.009,251View SEC Filing Icon  
4/12/2023John M ClimacoCEOBuy15,000$0.69$10,350.0045,010View SEC Filing Icon  
4/10/2023Jerzy GumulkaDirectorBuy7,173$0.74$5,308.027,173View SEC Filing Icon  
3/27/2023Waldemar PriebeMajor ShareholderSell5,000$1.09$5,450.00166,807View SEC Filing Icon  
3/24/2023Waldemar PriebeMajor ShareholderSell5,000$1.08$5,400.00171,807View SEC Filing Icon  
3/22/2023Waldemar PriebeMajor ShareholderSell5,000$1.08$5,400.00186,807View SEC Filing Icon  
3/20/2023Waldemar PriebeMajor ShareholderSell5,000$1.08$5,400.00196,807View SEC Filing Icon  
3/17/2023Waldemar PriebeMajor ShareholderSell5,000$1.13$5,650.00201,807View SEC Filing Icon  
3/15/2023Waldemar PriebeMajor ShareholderSell5,000$1.22$6,100.00211,807View SEC Filing Icon  
3/13/2023Waldemar PriebeMajor ShareholderSell5,000$1.30$6,500.00221,807View SEC Filing Icon  
3/10/2023Waldemar PriebeMajor ShareholderSell5,000$1.29$6,450.00226,807View SEC Filing Icon  
12/6/2021Christopher DownsCFOBuy5,000$0.94$4,700.00View SEC Filing Icon  
11/19/2021Christopher DownsCFOBuy4,500$1.15$5,175.00View SEC Filing Icon  
See Full Table
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
From Traders Agency   |   Ad
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Click here now for the full details of this stock that’s set to rocket in the AI revolution…

SEC Filings (Institutional Ownership Changes) for CNS Pharmaceuticals (NASDAQ:CNSP)

14.02% of CNS Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at CNSP by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

CNS Pharmaceuticals Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/13/2024Armistice Capital LLC122,000$0.16M0.0%N/A1.965%Search for SEC Filing on Google Icon
1/17/2024Smith Anglin Financial LLC50,000$64K0.0%N/A0.952%Search for SEC Filing on Google Icon
8/7/2023Acadian Asset Management LLC22,292$49K0.0%N/A1.000%Search for SEC Filing on Google Icon
7/12/2023FSM Wealth Advisors LLC16,334$38K0.0%N/A0.732%Search for SEC Filing on Google Icon
9/17/2021Virtu Financial LLC20,745$41K0.0%-49.8%0.076%Search for SEC Filing on Google Icon
8/13/2021Renaissance Technologies LLC432,109$0.85M0.0%-40.2%1.704%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC100,196$0.20M0.0%+64.8%0.395%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.599,309$1.18M0.0%+326.6%2.363%Search for SEC Filing on Google Icon
8/11/2021Commonwealth Equity Services LLC20,000$39K0.0%N/A0.079%Search for SEC Filing on Google Icon
5/19/2021Virtu Financial LLC41,310$99K0.0%N/A0.163%Search for SEC Filing on Google Icon
5/18/2021Citadel Advisors LLC92,404$0.22M0.0%N/A0.364%Search for SEC Filing on Google Icon
5/18/2021Jane Street Group LLC13,747$33K0.0%N/A0.054%Search for SEC Filing on Google Icon
5/17/2021Goldman Sachs Group Inc.11,566$28K0.0%N/A0.046%Search for SEC Filing on Google Icon
5/13/2021Renaissance Technologies LLC722,760$1.73M0.0%N/A2.850%Search for SEC Filing on Google Icon
5/13/2021Bank of New York Mellon Corp43,659$0.10M0.0%N/A0.172%Search for SEC Filing on Google Icon
5/12/2021Northern Trust Corp32,094$77K0.0%N/A0.127%Search for SEC Filing on Google Icon
5/12/2021Geode Capital Management LLC60,784$0.15M0.0%N/A0.240%Search for SEC Filing on Google Icon
2/16/2021Warberg Asset Management LLC14,000$25K0.0%N/A0.059%Search for SEC Filing on Google Icon
11/12/2020Essex Investment Management Co. LLC61,563$0.11M0.0%-13.5%0.370%Search for SEC Filing on Google Icon
5/4/2020Essex Investment Management Co. LLC71,494$0.15M0.0%-7.7%0.435%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
CNS Pharmaceuticals logo
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.
Read More on CNS Pharmaceuticals

Today's Range

Now: $0.21
Low: $0.19
High: $0.21

50 Day Range

MA: $0.31
Low: $0.20
High: $0.45

52 Week Range

Now: $0.21
Low: $0.19
High: $2.98

Volume

142,355 shs

Average Volume

369,723 shs

Market Capitalization

$2.23 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.67

Who are the company insiders with the largest holdings of CNS Pharmaceuticals?

CNS Pharmaceuticals' top insider shareholders include:
  1. Waldemar Priebe (Major Shareholder)
  2. John M Climaco (CEO)
  3. Christopher Downs (CFO)
  4. Jerzy Gumulka (Director)
Learn More about top insider investors at CNS Pharmaceuticals.
Global crypto currency reset (41 major banks signed up)
From Stansberry Research   |   Ad
Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...
 Here's everything you need to know.